Tumor-reactive T&#xa0;cell clonotype dynamics underlying clinical response to TIL therapy in melanoma

Skin Cancer

Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8(+) T-myeloid cell networks in melanoma

Sci Immunol

Barras D, Ghisoni E, Chiffelle J, Orcurto A, Dagher J, Fahr N, Benedetti F, Crespo I, Grimm AJ, Morotti M, Zimmermann S, Duran R, Imbimbo M, de Olza MO, Navarro B, Homicsko K, Bobisse S, Labes D, Tsourti Z, Andriakopoulou C, Herrera F, Pétremand R, Dummer R, Berthod G, Kraemer AI, Huber F, Thevenet J, Bassani-Sternberg M, Schaefer N, Prior JO, Matter M, Aedo V, Dromain C, Corria-Osorio J, Tissot S, Kandalaft LE, Gottardo R, Pittet M, Sempoux C, Michielin O, Dafni U, Trueb L, Harari A, Laniti DD, Coukos G

doi: 10.1126/sciimmunol.adg7995

Lymphoma

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Blood

Prasad R, Rehman A, Rehman L, Darbaniyan F, Blumenberg V, Schubert ML, Mor U, Zamir E, Schmidt S, Hayase T, Chia-Chi C, McDaniel LK, Flores I, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Wang ML, Jain P, Nastoupil LJ, Westin JR, Arora R, Turner JG, Khawaja F, Wu R, Dennison JB, Menges M, Hidalgo-Vargas M, Reid KM, Davila ML, Dreger P, Korell F, Schmitt A, Tanner MR, Champlin RE, Flowers CR, Shpall EJ, Hanash S, Neelapu SS, Schmitt M, Subklewe M, Fahrmann J, Stein-Thoeringer C, Elinav E, Jain MD, Hayase E, Jenq RR, Saini NY

doi: 10.1182/blood.2024025366

EHA 2024

Myeloproliferative Neoplasms (MPNs)

Innovative CAR T-cell therapy shows promising results in pre-clinical testing for myeloproliferative neoplasms

Skin Cancer

Melanoma clonal heterogeneity leads to secondary resistance after adoptive cell therapy with tumor-infiltrating lymphocytes

Cancer Immunol Res

König D, Sandholzer M, Uzun S, Zingg A, Ritschard R, Thut H, Glatz K, Kappos EA, Schaefer DJ, Kettelhack C, Passweg JR, Holbro A, Baur K, Medinger M, Buser A, Lardinois D, Jeker LT, Khanna N, Stenner F, Kasenda B, Homicsko K, Matter M, Rodrigues Mantuano N, Zippelius A, Läubli H

doi: 10.1158/2326-6066.CIR-23-0757

Skin Cancer

Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma

Immunooncol Technol

König D, Kasenda B, Sandholzer M, Chirindel A, Zingg A, Ritschard R, Thut H, Glatz K, Kappos EA, Schaefer D, Kettelhack C, Passweg J, Baur K, Holbro A, Buser A, Lardinois D, Jeker LT, Khanna N, Stenner F, Matter MS, Rodrigues Mantuano N, Binder M, Zippelius A, Läubli H

doi: 10.1016/j.iotech.2024.100728

Lymphoma

Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma

Haematologica

Benjamini O, Fried S, Shouval R, Flynn JR, Beyar-Katz O, Leslie LA, Zucherman T, Yerushalmi R, Shem-Tov N, Palomba ML, Danylesko I, Sdayoor I, Malka H, Itzhaki O, Suh H, Devlin SM, Marcus R, Dahi PB, Jacoby E, Shah GL, Sauter CS, Ip A, Perales MA, Nagler A, Shimoni A, Scordo M, Avigdor A

doi: 10.3324/haematol.2023.284664

Multiple Myeloma (MM)

Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study

Br J Haematol

Zhou X, Wagner V, Scheller L, Stanojkovska E, Riedhammer C, Xiao X, Steinhardt MJ, Vogt C, Nerreter S, Eisele F, John M, Munawar U, Kadel SK, Mersi J, Ruckdeschel A, Schimanski S, Haertle L, Waldschmidt JM, Han S, Topp M, Duell J, Einsele H, Riedel A, Kortüm KM, Rasche L

doi: 10.1111/bjh.19515

Lymphoma

Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy

Br J Haematol

de la Iglesia-San Sebastián I, López-Esteban M, Bastos-Oreiro M, Fernández de Córdoba-Oñate S, Gutierrez M, Carbonell D, Bailén R, Gómez-Centurión I, Fernández-Caldas P, Castilla L, Anguita J, Kwon M, García-Sanz R, Buño I, Martínez-Laperche C

doi: 10.1111/bjh.19916

Multiple Myeloma (MM)

Tumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic Tumor Volume determine myeloma CAR-T outcomes

Blood

Freeman CL, Noble J, Menges M, Villanueva R, Nakashima JY, Figura NB, Tonseth RP, Idiaquez DW, Skelson L, Smith EC, Abraham-Miranda J, Corallo S, De Avila G, Castaneda Puglianini O, Liu HD, Alsina M, Nishihori T, Shain KH, Baz RC, Blue BJ, Grajales-Cruz A, Koomen JM, Atkins RM, Hansen DK, Siqueira Silva A, Kim J, Balagurunathan Y, Locke FL

doi: 10.1182/blood.2024024965

Oncology · Hematology

Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma

Related content

Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8(+) T-myeloid cell networks in melanoma

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Innovative CAR T-cell therapy shows promising results in pre-clinical testing for myeloproliferative neoplasms

Melanoma clonal heterogeneity leads to secondary resistance after adoptive cell therapy with tumor-infiltrating lymphocytes

Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma

Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma

Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study

Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy

Tumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic Tumor Volume determine myeloma CAR-T outcomes